Navigation Links
Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding
Date:10/13/2009

NEWNAN, Ga., Oct. 13 /PRNewswire/ -- CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b )

(Photo: http://www.newscom.com/cgi-bin/prnh/20090916/CL76973)

In Europe, Embozene(TM) Microspheres are now approved for the treatment of liver cancer, uterine fibroids, tumors of the head, neck, torso, and skeletal system; for bleeding and trauma, including nosebleeds; and for reducing the amount of bleeding before any surgery other than in the central nervous system. "Physicians throughout Europe, in Japan, the Middle East, and the United States have used Embozene(TM) Microspheres successfully to treat a variety of conditions. Physicians report that patients have less pain, speedy recovery, and are back to their regular activities sooner," said Thomas A. Gordy, President and chief Executive Officer of CeloNova BioSciences. "With the addition of a 75 micron microsphere, CeloNova now has three distinct sizes of Embozene(TM) Microspheres for physicians to use in the smallest blood vessels. With ten sizes that range from 40 microns to 1300 microns, this product is the most versatile in the market."

Embozene(TM) Microspheres are tiny, round, hydrogel beads with a coating of CeloNova's unique polymer, Polyzene®-F. The smallest ones cannot be detected by the naked eye while the largest beads are only 1300 microns (one-twentieth of an inch) in diameter. A specially trained physician, an interventional radiologist, injects them inside a blood vessel to stop the blood supply to a tumor or where there is unwanted bleeding. This minimally invasive treatment, called embolization, often replaces surgery.

About Embozene(TM) Microspheres

Embozene(TM) Microspheres are the first and only microspheres to be color-enhanced with a different color for each size for increased procedural safety, efficiency, and visibility. CeloNova's Embozene(TM) Microspheres consist of a hydrogel core and an exterior shell made from Polyzene®-F, CeloNova's proprietary polymer which is known to be anti-inflammatory and bacterial-resistant. Four design features distinguish Embozene(TM) Microspheres from other spherical embolics: biocompatibility, precise calibration, stable suspension, and structural stability.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. For more information, please visit www.celonova.com.

    CONTACT:
    Teresa Wilson
    CeloNova BioSciences, Inc.
    +1 (678) 895-6486
    +1 (770) 502-0304
    twilson@celonova.com

SOURCE CeloNova BioSciences, Inc.


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
2. Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment
3. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
4. Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative
5. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
6. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
7. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
8. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
9. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
10. Positive Results Published Using AtriCure Minimally Invasive Products
11. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ALEXANDRIA, Va. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... year by the Academy of Managed Care Pharmacy ... care organizations can better address the opioid addiction ... Medication Assisted Therapies (MAT). ATAG,s newly ... in Improving Access to Naloxone," addresses many issues ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health Corporation ... Analyst Day in New York City on Thursday, December 15, 2016, beginning ... leadership team will provide an in-depth review of the ... value. The company will also discuss 2017 earnings guidance ... webcast of the event will be broadcast simultaneously on ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 02, 2016 , ... Two years ago, Arizona State University ... live by 1 million viewers and won numerous honors, including the region’s top ... the Walter Cronkite School of Journalism and Mass Communication are following up their ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... "Pro3rd Accents ... FCPX editors to create versatile lower third titles with just a few clicks of ... Accents Volume 2 includes 30 lower third animations. Choose from various styles with accented ...
Breaking Medicine News(10 mins):